<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Gastrointestinal (GI) <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> account for nearly one-fourth of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> in the United States and approximately 30% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Use of combination cytotoxic therapy offers a modest improvement in survival, but the prognosis and long-term survival of most patients with GI <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> remains poor </plain></SENT>
<SENT sid="2" pm="."><plain>In certain GI <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, therapies that target members of the HER family of receptors have positively impacted patient care </plain></SENT>
<SENT sid="3" pm="."><plain>AREAS COVERED: In this review, we discuss the significance of the HER family of receptors in esophagogastric, hepatobiliary, pancreatic, and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> and explain the rationale supporting the use of monoclonal antibodies (mAbs) and small molecule <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> (TKIs) to inhibit HER activation and downstream events that contribute to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> proliferation, migration, and survival </plain></SENT>
<SENT sid="4" pm="."><plain>EXPERT OPINION: Despite recent advances, the treatment of GI <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> remains challenging </plain></SENT>
<SENT sid="5" pm="."><plain>Therapies targeting the HER family of receptors have been extensively studied in these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> with inconsistent results </plain></SENT>
<SENT sid="6" pm="."><plain>The rationale behind varied <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> responses with these agents remains uncertain </plain></SENT>
<SENT sid="7" pm="."><plain>We believe that additional studies are needed to identify biomarkers that could help identify a population of patients who would be more responsive to a given therapy </plain></SENT>
</text></document>